Icosavax has launched with $51m in series A funding from Sanofi Ventures and others to move a vaccine for respiratory syncytial virus into a phase 1b trial.
US-based vaccine developer Icosavax emerged from stealth yesterday with $51m of series A funding from investors including Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi.
Qiming Venture Partners USA led the round, which was also backed by fellow venture capital firm NanoDimension, private equity firm Adams Street Partners and undisclosed existing investors.
Spun out University of Washington (UW) in 2018, Icosavax is developing vaccines for infectious diseases using molecules known as virus-like particles (VLPs), which closely resemble viruses…
